医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KineMed Announces License Agreement to Develop Late-Stage Synthetic Ghrelin

2015年09月24日 PM09:00
このエントリーをはてなブックマークに追加


 

EMERYVILLE, Calif. & TOKYO

KineMed, Inc. announced today that it has entered into an agreement with BioPharma Forest, Inc. to develop and commercialize synthetic Ghrelin.

Under the terms of the Agreement, KineMed will develop the late-stage appetite stimulating agent, synthetic Ghrelin, for indications associated with muscle wasting. KineMed will apply its platform technology to assess skeletal muscle protein synthesis and whole body muscle mass to provide key decision-making data in an initial Phase II trial in 2016.

“Acquiring this late-stage asset furthers our purpose as a strong drug development company,” said Patrick Doyle, President of KineMed. “By adding Ghrelin to our pipeline, we are leveraging our strengths in the area of muscle related disorders,” he added.

KineMed has world leading knowledge and experience in the muscle wasting area and believes its expertise, combined with application of its dynamic proteomic biomarkers of muscle anabolism, enables KineMed to carry out rapid proof-of-concept trials with a high degree of confidence for early detection and predictive efficacy in treating muscle wasting.

“Synthetic Ghrelin is a powerful orexigenic agent with strong anabolic effect,” added William Evans, Ph.D., President of KineMed’s Muscle & Wellness Division and a world leader in muscle metabolism and nutrition. “We are excited about applying this new medicine in patients with muscle wasting. This represents a new therapy to treat those patients who have lost both body weight and muscle mass, in a condition where there is no currently approved drug for this purpose.”

Professor Kenji Kangawa, who made the original discovery of Ghrelin, added, “Ghrelin has many positive metabolic effects, and its development as a medicine to treat patients with weight loss and muscle wasting has great promise; however, it is essential that Ghrelin is evaluated in clinical trials that select the right patient population to show the true benefit of this new medicine. I am delighted that KineMed will be applying its deep knowledge in this area to do exactly that.”

Financial terms of the agreement were not released.

About KineMed, Inc.

KineMed is creating a pipeline of high-value drug assets in neurodegenerative, muscle-wasting, and fibrotic diseases. The pipeline today is focused on two Phase II trials in 2016. We apply our dynamic proteomics platform to rapidly detect target engagement, track disease progression and provide data that are highly predictive of late-stage success after three months of treatment, thus providing key data in 2016.

For more information about KineMed, please visit: www.kinemed.com.

About Biopharma Forest, Inc.

Biopharma Forest is a Japanese venture company created to commercialize synthetic Ghrelin which was invented by Professor Kenji Kangawa, Director General, National Cerebral and Cardiovascular Center Research Institute and Professor, Kyoto University Graduate School of Medicine in Japan.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150924005044/en/

CONTACT

KineMed, Inc.
Patrick Doyle, 510-655-6525 ext. 172
President
pdoyle@kinemed.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • COVID WHO Investigation: A Smoke Screen for China, says AHF
  • New Frontier Health Corporation Announces Receipt of Clarification to Preliminary Non-Binding “Going Private” Proposal
  • 美国项目管理协会发布的《 2021年大趋势》聚焦项目将如何平衡新兴的颠覆力量
  • GNT Pharma’s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome
  • GNTファーマのGedaCure®が犬の認知障害症候群の治療薬として承認される